Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT07092605

Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures

The goal of this clinical study has two objectives. The Primary Objective is to evaluate the effectiveness of microdosed GLP-1 receptor agonists in improving measures of health, quality of life, and longevity. The Secondary Objective: To assess the impact of these therapies on weight management practices and metabolic health.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Longevity Agnosia Alertness Immune Health Inflammation Mood Nervous System Diseases Neurobehavioral Manifestations Neurologic Manifestations Pain Management Pathologic Processes Pathological Conditions, Signs and Symptoms Perceptual Disorders Quality of Life Signs and Symptoms Weight Management

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

AgelessRx

Ann Arbor, Michigan, 48104, United States

About this study

Participants will be assigned to one of three groups: 1) control, 2) microdosed sublingual semaglutide, 3) microdosed subcutaneous semaglutide. At baseline and every 4 weeks thereafter, participants will be asked to complete surveys on health, wellness, mood, demographic information, and similar. Additionally, at baseline and every 12 weeks thereafter, they will be requested to complete evaluative blood work to measure CBC, CMP, and standard health biomarker panels (e.g., cholesterol, glucose, creatinine, sodium, potassium). From baseline throughout the duration of the study, participants will be given the option to share data from wearable activity and health trackers with the research team for greater accuracy in evaluating measures of activity, sleep, heart rate, and similar.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • New or existing AgelessRx patient
  • Adults (aged 18-65)
  • Any sex
  • Any ethnicity
  • BMI ≥ 20 kg/m^2
  • Interest in taking microdoses of semaglutide for health and longevity improvement with no intent to seek weight loss improvement.

Exclusion criteria

  • Individuals who are denied a longevity product by the AgelessRx medical team will not be asked to participate in any product specific test(s) or questionnaire(s)
  • History of bariatric surgery
  • Use of other weight-loss medications currently or within the past 6 months
  • Contraindications to semaglutide
  • Significant psychiatric illness that may affect participation
  • Pregnant or breastfeeding individuals

Treatment and study plan

GLP-1

Drug

Sublingual GLP1 (weekly), Subcutaneous GLP1 (weekly), Sublingual Placebo (weekly) for up to 6 months.

Other names: Semaglutide

Placebo

Drug

Sublingual Placebo (weekly) for up to 6 months

Primary outcomes

  1. Change in self-reported pain levels in participants microdosing GLP1s

    Time frame: 6 months

    Participants will complete an extensive medical questionnaire every 4 weeks over a 24-week period to monitor self-reported pain levels

  2. Concentration of complete blood cells, as a measure of immunological health, in participants microdosing GLP1s

    Time frame: 6 months

    CBC panel will be analyzed every 12 weeks over a 24-week period, reported in thousands of cells per microliter with the change from baseline reported as percent deviation and compared to normalized range of healthy individuals

  3. Concentration of basic metabolites (cholesterol, glucose, creatinine, sodium, potassium), as a measure of immunological health, in participants microdosing GLP1s

    Time frame: 6 months

    BMP panel will be analyzed every 12 weeks over a 24-week period, reported in mg/dL with the change from baseline reported as percent deviation and compared to a normalized range of healthy individuals

  4. Change in mood in participants microdosing GLP1s

    Time frame: 6 months

    Mood will be assessed every 4 weeks over a 24-week period using the SF-36 standardized questionnaire with deviation reported as percent change from baseline

  5. Change in heart rate variability in participants microdosing GLP1s

    Time frame: 6 months

    Participants will wear health devices with data monitored every 4 weeks over a 24-week period to observe change in heart rate variability, being defined as the variability of a participant's resting heart rate. Variability will be measured as an average deviation from baseline heart rate at each timepoint and reported as percent difference.

  6. Changes in sleep patterns in participants microdosing GLP1s

    Time frame: 6 months

    Wearable health device data will be monitored over the 24-week period assessing REM vs non-REM sleep and reported as a ratio

  7. Change in frequency of physical activity in participants microdosing GLP1s

    Time frame: 6 months

    The change in frequency of physical activity, defined as a departure from baseline in time spent performing moderate to rigorous physical exercise, will be captured via wearable health device data and will be reported as percent difference from baseline in steps taken.

  8. Change in frequency of physical activity in participants microdosing GLP1s

    Time frame: 6 months

    The change in frequency of physical activity, defined as a departure from baseline in time spent performing moderate to rigorous physical exercise, will be captured via wearable health device data and will be reported as percent difference from baseline in calories burned.

Secondary outcomes

  1. Variation in concentration of metabolic health biomarkers in participants microdosing GLP1s

    Time frame: 6 months

    Changes in HbA1c levels will be assessed every 12 weeks and reported as a percent deviation from baseline

  2. Variation in concentration of metabolic health biomarkers in participants microdosing GLP1s

    Time frame: 6 months

    Changes in LDL cholesterol levels will be assessed every 12 weeks and reported as a percent deviation from baseline

  3. Variation in concentration of metabolic health biomarkers in participants microdosing GLP1s

    Time frame: 6 months

    Changes in HDL cholesterol levels will be assessed every 12 weeks and reported as a percent deviation from baseline

  4. Variation in concentration of metabolic health biomarkers in participants microdosing GLP1s

    Time frame: 6 months

    Changes in triglyceride levels will be assessed every 12 weeks and reported as a percent deviation from baseline

Sponsors and collaborators

Lead sponsor

AgelessRx

Industry

Registry information

Official study title

Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures: For Use in Healthy Individuals Ages 18-65 Who Seek to Improve Their Health and Longevity Through Low-dose (Microdosed) GLP1 Receptor Agonists

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Jul 30, 2025
Registry last updated
Jul 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.